ResMed Inc. (NYSE:RMD) Shares Sold by XY Capital Ltd

XY Capital Ltd cut its stake in ResMed Inc. (NYSE:RMD - Free Report) by 49.0% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 12,111 shares of the medical equipment provider's stock after selling 11,628 shares during the period. ResMed makes up 1.0% of XY Capital Ltd's investment portfolio, making the stock its 15th largest position. XY Capital Ltd's holdings in ResMed were worth $2,957,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the stock. Empirical Finance LLC grew its position in ResMed by 3.5% during the first quarter. Empirical Finance LLC now owns 5,232 shares of the medical equipment provider's stock valued at $1,036,000 after acquiring an additional 179 shares during the period. Envestnet Portfolio Solutions Inc. increased its position in ResMed by 1.9% during the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 3,188 shares of the medical equipment provider's stock worth $631,000 after purchasing an additional 60 shares in the last quarter. Empowered Funds LLC increased its position in ResMed by 88.8% during the 1st quarter. Empowered Funds LLC now owns 2,764 shares of the medical equipment provider's stock worth $547,000 after purchasing an additional 1,300 shares in the last quarter. SG Americas Securities LLC raised its holdings in ResMed by 211.1% in the first quarter. SG Americas Securities LLC now owns 19,625 shares of the medical equipment provider's stock valued at $3,886,000 after buying an additional 13,316 shares during the period. Finally, Forsta AP Fonden lifted its position in ResMed by 10.6% during the first quarter. Forsta AP Fonden now owns 29,300 shares of the medical equipment provider's stock valued at $5,802,000 after buying an additional 2,800 shares in the last quarter. 54.98% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on RMD shares. Baird R W raised shares of ResMed to a "strong-buy" rating in a research report on Tuesday, September 24th. StockNews.com upgraded ResMed from a "hold" rating to a "buy" rating in a report on Tuesday, October 15th. KeyCorp boosted their price objective on ResMed from $251.00 to $266.00 and gave the stock an "overweight" rating in a research note on Friday, October 25th. Royal Bank of Canada upped their target price on ResMed from $224.00 to $232.00 and gave the stock a "sector perform" rating in a research report on Friday, October 25th. Finally, Bank of America raised their target price on ResMed from $240.00 to $270.00 and gave the company a "buy" rating in a report on Thursday, September 26th. One research analyst has rated the stock with a sell rating, five have given a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, ResMed has a consensus rating of "Moderate Buy" and a consensus price target of $225.70.

Insiders Place Their Bets

In other news, insider Kaushik Ghoshal sold 5,000 shares of the firm's stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $252.56, for a total value of $1,262,800.00. Following the transaction, the insider now directly owns 21,788 shares in the company, valued at approximately $5,502,777.28. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, insider Kaushik Ghoshal sold 5,000 shares of the stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $252.56, for a total transaction of $1,262,800.00. Following the sale, the insider now directly owns 21,788 shares in the company, valued at approximately $5,502,777.28. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Peter C. Farrell sold 2,000 shares of the business's stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $248.74, for a total value of $497,480.00. Following the transaction, the director now owns 83,204 shares of the company's stock, valued at $20,696,162.96. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 62,260 shares of company stock valued at $14,887,967 over the last 90 days. 0.71% of the stock is owned by company insiders.

ResMed Stock Up 1.5 %

Shares of RMD traded up $3.84 during trading on Friday, reaching $252.38. The company's stock had a trading volume of 930,321 shares, compared to its average volume of 1,050,988. The company has a quick ratio of 1.91, a current ratio of 2.92 and a debt-to-equity ratio of 0.13. The company has a fifty day moving average of $243.36 and a two-hundred day moving average of $222.08. The company has a market cap of $37.05 billion, a price-to-earnings ratio of 33.43, a P/E/G ratio of 1.80 and a beta of 0.69. ResMed Inc. has a twelve month low of $140.81 and a twelve month high of $260.49.

ResMed (NYSE:RMD - Get Free Report) last announced its quarterly earnings data on Thursday, October 24th. The medical equipment provider reported $2.20 earnings per share for the quarter, beating the consensus estimate of $2.03 by $0.17. ResMed had a return on equity of 25.53% and a net margin of 23.15%. The firm had revenue of $1.22 billion during the quarter, compared to analyst estimates of $1.19 billion. During the same period in the previous year, the company earned $1.64 earnings per share. ResMed's quarterly revenue was up 11.1% on a year-over-year basis. On average, sell-side analysts predict that ResMed Inc. will post 9.22 EPS for the current fiscal year.

ResMed Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 12th. Investors of record on Thursday, November 7th will be paid a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 0.84%. The ex-dividend date is Thursday, November 7th. ResMed's dividend payout ratio (DPR) is presently 28.08%.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.